Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$147.13 USD

147.13
5,659,919

+0.05 (0.03%)

Updated Jun 10, 2024 04:00 PM ET

After-Market: $147.10 -0.03 (-0.02%) 5:02 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (154 out of 248)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for JNJ

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Johnson & Johnson [JNJ]

Reports for Purchase

Showing records 441 - 460 ( 500 total )

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 441

07/17/2012

Company Report

Pages: 9

Managed Higher EPS Despite a More Severe Drag from Currency and Weakness in Some Areas

Provider: J.J.B. Hilliard, W.L. Lyons

Analyst: O'NEIL S

Price: 25.00

Research Provided by a Third Party

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 442

06/29/2012

Company Report

Pages: 12

Price: 24.95

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 443

04/27/2012

Company Report

Pages: 11

Price: 24.95

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 444

04/23/2012

Company Report

Pages: 14

Overall performance in CY12 expected to come under pressure due to negative currency impact

Provider: FIRST GLOBAL

Analyst: THOMAS K

Price: 50.00

Research Provided by a Third Party

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 445

04/19/2012

Company Report

Pages: 11

Price: 24.95

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 446

04/18/2012

Company Report

Pages: 2

JNJ: Q1 Results OK and Improving from Here BUY

Provider: G.RESEARCH, LLC

Price: 10.00

Research Provided by a Third Party

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 447

04/17/2012

Company Report

Pages: 10

First Quarter EPS Higher on a Small Decline in Revenue

Provider: J.J.B. Hilliard, W.L. Lyons

Analyst: O'NEIL S

Price: 25.00

Research Provided by a Third Party

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 448

04/17/2012

Industry Report

Pages: 4

Specialty Pharmaceuticals Short Interest Analysis

Provider: AURIGA USA

Price: 10.00

Research Provided by a Third Party

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 449

03/30/2012

Industry Report

Pages: 5

LIFE SCIENCES -The Week Ahead in Life Sciences - Upcoming Events for the Week of April 1

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 450

02/02/2012

Company Report

Pages: 15

Overall performance expected to come under pressure in CY12 due to negative currency impact, as against currency benefits enjoyed in CY11...

Provider: FIRST GLOBAL

Analyst: THOMAS K

Price: 50.00

Research Provided by a Third Party

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 451

02/02/2012

Company Report

Pages: 11

Price: 24.95

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 452

01/25/2012

Company Report

Pages: 2

JNJ: Uneventful Q4 results and conservative 2012 guidance

Provider: G.RESEARCH, LLC

Price: 10.00

Research Provided by a Third Party

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 453

01/25/2012

Company Report

Pages: 11

Price: 24.95

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 454

01/24/2012

Company Report

Pages: 10

Solid Fourth Quarter Results. 2012 Expectations Moderated Somewhat.

Provider: J.J.B. Hilliard, W.L. Lyons

Analyst: O'NEIL S

Price: 25.00

Research Provided by a Third Party

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 455

01/16/2012

Company Report

Pages: 11

Price: 24.95

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 456

01/10/2012

Daily Note

Pages: 5

In Today''s Morning Exchange

Provider: KAUFMAN BROTHERS

Price: 10.00

Research Provided by a Third Party

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 457

11/04/2011

Industry Report

Pages: 3

Day 2, NASS 2011: NuVasive Outlines Strategy for Continued Growth & Market Share Gains

Provider: KAUFMAN BROTHERS

Analyst: CERVANTES V

Price: 10.00

Research Provided by a Third Party

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 458

11/03/2011

Industry Report

Pages: 5

Day 1, NASS 2011: While Tempered, Spine Industry Uncertainties Persist with Relief Rather Elusive

Provider: KAUFMAN BROTHERS

Analyst: CERVANTES V

Price: 10.00

Research Provided by a Third Party

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 459

10/26/2011

Company Report

Pages: 10

Price: 24.95

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 460

10/21/2011

Company Report

Pages: 15

Well positioned to step back on growth trajectory from CY12 onwards......

Provider: FIRST GLOBAL

Analyst: THOMAS K

Price: 50.00

Research Provided by a Third Party